11/25/09 16:31 | 11/23/09 | ENZN | Enzon Pharmaceuticals Inc | DE | Health | BioPrd | Biological Products, (No Diag | Buchalter Jeffrey H | NJ | DO | CB,CEO,P | M.d | 0 | 0.00 | 7 | 36 | 7 | 541 | D | 12 | 129 | 40 | 43 | 15 | 25 | 7 | 1 | -2 | -3 | 3 | -10 | 3 | 8 |
4/7/09 15:42 | 4/3/09 | ENZN | Enzon Pharmaceuticals Inc | DE | Health | BioPrd | Biological Products, (No Diag | Buchalter Jeffrey H | NJ | DO | CB,CEO | M.d | 0 | 0.00 | 2 | 59 | 13 | 522 | D | -28 | -36 | -8 | 1 | 2 | -8 | -9 | 0 | -3 | -7 | -3 | 33 | 46 | 76 |
11/25/08 15:53 | 11/23/08 | ENZN | Enzon Pharmaceuticals Inc | DE | Health | BioPrd | Biological Products, (No Diag | Buchalter Jeffrey H | NJ | DO | CB,CEO,P | M.d | 0 | 0.00 | 3 | 36 | 8 | 489 | D | -45 | -51 | -48 | -50 | -7 | -7 | 28 | 13 | 5 | 0 | 27 | 17 | 64 | 129 |
11/13/08 17:28 | 11/13/08 | ENZN | Enzon Pharmaceuticals Inc | DE | Health | BioPrd | Biological Products, (No Diag | Buchalter Jeffrey H | NJ | DO | CB,CEO,P | P | 164 | 3.28 | 2 | 50 | 12 | 453 | D | -62 | -69 | -66 | -67 | -56 | -41 | -38 | -30 | 6 | 15 | 75 | 113 | 98 | 210 |
8/21/07 12:22 | 8/20/07 | ENZN | Enzon Pharmaceuticals Inc | DE | Health | BioPrd | Biological Products, (No Diag | Buchalter Jeffrey H | NJ | DO | CB,CEO,P | P | 37 | 7.46 | 7 | 5 | 3 | 203 | D | 8 | -1 | -8 | -8 | 1 | 8 | 14 | 10 | 5 | 5 | 5 | 21 | 8 | 17 |
3/7/06 18:17 | 3/7/06 | ENZN | Enzon Pharmaceuticals Inc | DE | Health | BioPrd | Biological Products, (No Diag | Buchalter Jeffrey H | NJ | DO | CB,CEO,P | P | 69 | 6.86 | 2 | 10 | 11 | 98 | | | | | | | | | | 2 | -1 | 23 | 8 | 19 | 16 |
6/10/05 17:17 | 6/10/05 | ENZN | Enzon Pharmaceuticals Inc | DE | Health | BioPrd | Biological Products, (No Diag | Buchalter Jeffrey H | NJ | DO | CEO | P | 58 | 5.75 | 3 | 10 | 13 | 88 | D | -58 | -54 | -58 | -45 | -24 | -11 | -3 | 1 | 2 | 18 | 31 | 29 | 29 | 31 |
9/29/04 17:43 | 9/29/04 | ILXO | Ilex Oncology Inc | DE | Health | BioPrd | Biological Products, (No Diag | Buchalter Jeffrey H | | O | P,CFO | S | -2,525 | 25.25 | 0 | -100 | -54 | 85 | D | | | | | | | | | | | | | | |